Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Cancer Letters, 02/24/2012
Reckamp KL – With the approval of the antiangiogenic antibody bevacizumab in non–small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second–line therapies have the potential to improve overall survival and quality of life over best supportive care alone.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.